Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Solitomab

Known as: Anti-EpCAM BiTE 
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct… Expand
Is this relevant?
Review
2017
Review
2017
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
BACKGROUND Uterine serous carcinoma is an aggressive form of endometrial cancer that carries an extremely poor prognosis… Expand
Is this relevant?
Review
2016
Review
2016
Bispecific T-cell engager (BiTE(®)) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor… Expand
Is this relevant?
2015
2015
BackgroundUterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
BACKGROUND Solitomab is a novel, bispecific, single-chain antibody that targets epithelial cell adhesion molecule (EpCAM) on… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?